Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
Age at cancer diagnosis
BRCA1 germline pathogenic sequence variants
Incomplete penetrance
Modifier factors
Journal
Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
10
07
2020
accepted:
03
11
2020
pubmed:
10
11
2020
medline:
15
12
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Germline pathogenic sequence variants (PSVs) in BRCA1 substantially increase risk for developing breast (BC) and ovarian cancer (OvC). Yet, incomplete penetrance suggests that modifier factors affect phenotypic expression of mutant BRCA1 alleles. Analysis of identical BRCA1 PSV carriers of diverse ethnicities may provide further evidence for modifier factors. Female carriers of the 185delAG BRCA1 PSV identified through high-risk clinics in Israel, and Manchester England from 1998-2018 were eligible. Data were retrieved from patients records and confirmed (in Israel) by cross referencing with the Israeli National Cancer Registry. Overall, 2503 female carriers were included: 1715 (71.4%) Ashkenazi Jews (AJ), 201 (8.3%) Iraqi Jews and 383 (15.9%) of mixed ethnicity. In 102 (4.2%) cases ethnicity could not be ascertained. Of Israeli AJ carriers 649 (37.8%), 256 (14.9%) and 62 (3.6%) were diagnosed with BC, OvC or both cancers, respectively. For the Iraqi Jews these frequencies were 76 (37.8%), 43 (21.4%), and 8 (3.98%), respectively. Age at diagnosis of BC in AJ and Iraqi Jews was 46.7 ± 12.3 years and 52.8 ± 12.2 years, respectively (p = 0.001). For OvC age at diagnosis for AJ was 53.5 ± 10.7 years and for Iraqi Jews 50.1 ± 8.8 years (p = 0.0027). No differences in these parameters were noted between English Jews (n = 110) and non-Jews (n = 32). Age at diagnosis of BC and OvC differs between AJ and Iraqi Jews who carry an identical BRCA1 PSV. This finding supports the existence of modifier factors that may be ethnic specific.
Identifiants
pubmed: 33165727
doi: 10.1007/s10689-020-00216-y
pii: 10.1007/s10689-020-00216-y
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-194Subventions
Organisme : Department of Health
ID : IS-BRC-1215–20007
Pays : United Kingdom
Références
Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112
doi: 10.1001/jama.2017.7112
pubmed: 28632866
Armstrong AC, Evans GD (2014) Management of women at high risk of breast cancer. BMJ. https://doi.org/10.1136/bmj.g2756
doi: 10.1136/bmj.g2756
pubmed: 25227507
pmcid: 3898159
Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 96(1):11–15. https://doi.org/10.1038/sj.bjc.6603535
doi: 10.1038/sj.bjc.6603535
pubmed: 17213823
pmcid: 2360226
Rebbeck TR, Mitra N, Wan F et al (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. https://doi.org/10.1001/jama.2014.5985
doi: 10.1001/jama.2014.5985
pubmed: 25849179
pmcid: 4537700
Chenevix-Trench G, Milne RL, Antoniou AC et al (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the consortium of investigators of modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 9(2):104. https://doi.org/10.1186/bcr1670
doi: 10.1186/bcr1670
pubmed: 17466083
pmcid: 1868919
Couch FJ, Wang X, McGuffog L et al (2013) Genome-wide association study in brca1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLOS Genet 9(3):e1003212. https://doi.org/10.1371/journal.pgen.1003212
doi: 10.1371/journal.pgen.1003212
pubmed: 23544013
pmcid: 3609646
Kuchenbaecker KB, McGuffog L, Barrowdale D et al (2017) Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw302
doi: 10.1093/jnci/djw302
pubmed: 28376175
pmcid: 5408990
Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514
pubmed: 9042909
pmcid: 1712523
Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185–187. https://doi.org/10.1038/ng1096-185
doi: 10.1038/ng1096-185
pubmed: 8841191
Mavaddat N, Peock S, Frost D et al (2013) Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. https://doi.org/10.1093/jnci/djt095
doi: 10.1093/jnci/djt095
pubmed: 23628597
Finkelman BS, Rubinstein WS, Friedman S et al (2012) Breast and ovarian cancer risk and risk reduction in jewish BRCA1/2 mutation carriers. J Clin Oncol 30(12):1321–1328. https://doi.org/10.1200/JCO.2011.37.8133
doi: 10.1200/JCO.2011.37.8133
pubmed: 22430266
pmcid: 3341145
Modan B, Gak E, Sade-Bruchim RB et al (1996) High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. JAMA 276(22):1823–1825. https://doi.org/10.1001/jama.1996.03540220047029
doi: 10.1001/jama.1996.03540220047029
pubmed: 8946903
Fortner RT, Poole EM, Wentzensen NA et al (2019) Ovarian cancer risk factors by tumor aggressiveness: an analysis from the ovarian cancer cohort consortium. Int J Cancer 145(1):58–69. https://doi.org/10.1002/ijc.32075
doi: 10.1002/ijc.32075
pubmed: 30561796
pmcid: 6488363
Anothaisintawee T, Wiratkapun C, Lerdsitthichai P et al (2013) Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 25(5):368–387. https://doi.org/10.1177/1010539513488795
doi: 10.1177/1010539513488795
pubmed: 23709491
Hamdi Y, Soucy P, Kuchenbaeker KB et al (2017) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161(1):117–134. https://doi.org/10.1007/s10549-016-4018-2
doi: 10.1007/s10549-016-4018-2
pubmed: 27796716
Lilyquist J, Ruddy KJ, Vachon CM, Couch FJ (2018) Common genetic variation and breast cancer risk—past, present, and future. Cancer Epidemiol Biomarkers Prev 27(4):380–394. https://doi.org/10.1158/1055-9965.EPI-17-1144
doi: 10.1158/1055-9965.EPI-17-1144
pubmed: 29382703
pmcid: 5884707
Laitman Y, Feng B-J, Zamir IM et al (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21(2):212–216. https://doi.org/10.1038/ejhg.2012.124
doi: 10.1038/ejhg.2012.124
pubmed: 22763381
Weitzel JN, Clague J, Martir-Negron A et al (2013) Prevalence and Type of BRCA mutations in hispanics undergoing genetic cancer risk assessment in the Southwestern United States: a report from the clinical cancer genetics community research network. J Clin Oncol 31(2):210–216. https://doi.org/10.1200/JCO.2011.41.0027
doi: 10.1200/JCO.2011.41.0027
pubmed: 23233716
Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K (2009) BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci 34(3):415–422. https://doi.org/10.1007/s12038-009-0048-9
doi: 10.1007/s12038-009-0048-9
pubmed: 19805903
Cancer Incidence Table. https://www.health.gov.il/UnitsOffice/HD/ICDC/ICR/CancerIncidence/Pages/Breast_Invasive.aspx . Accessed 22 March 2020.
Cancer Incidence Table. https://www.health.gov.il/UnitsOffice/HD/ICDC/ICR/CancerIncidence/Pages/Ovary.aspx . Accessed March 22, 2020.
Cancer Incidence Table. https://www.health.gov.il/UnitsOffice/HD/ICDC/ICR/CancerIncidence/Pages/default.aspx . Accessed 22 March 2020.